| Mineralocorticoid receptor and cardiovascular disease M Buonafine, B Bonnard, F Jaisser American Journal of Hypertension 31 (11), 1165-1174, 2018 | 99 | 2018 |
| Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases J Barrera-Chimal, B Bonnard, F Jaisser Annual Review of Physiology 84, 585-610, 2022 | 42 | 2022 |
| Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice B Bonnard, M Pieronne-Deperrois, Z Djerada, S Elmoghrabi, P Kolkhof, ... Journal of molecular and cellular cardiology 121, 124-133, 2018 | 37 | 2018 |
| Effect of acute and chronic aldosterone exposure on the retinal pigment epithelium-choroid complex in rodents J Canonica, C Mehanna, B Bonnard, L Jonet, E Gelize, JP Jais, F Jaisser, ... Experimental eye research 187, 107747, 2019 | 27 | 2019 |
| The absence of endothelial sodium channel α (αENaC) reduces renal ischemia/reperfusion injury A Tarjus, C González-Rivas, I Amador-Martínez, B Bonnard, ... International Journal of Molecular Sciences 20 (13), 3132, 2019 | 20 | 2019 |
| A new role for the aldosterone/mineralocorticoid receptor pathway in the development of mitral valve prolapse J Ibarrola, A Garcia-Peña, L Matilla, B Bonnard, R Sádaba, V Arrieta, ... Circulation research 127 (3), e80-e93, 2020 | 18 | 2020 |
| Neutrophil gelatinase-associated lipocalin from macrophages plays a critical role in renal fibrosis via the CCL5 (chemokine ligand 5)-Th2 cells-IL4 (Interleukin 4) pathway B Bonnard, J Ibarrola, I Lima-Posada, A Fernández-Celis, M Durand, ... Hypertension 79 (2), 352-364, 2022 | 16 | 2022 |
| Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models B Bonnard, E Martínez-Martínez, A Fernández-Celis, ... Scientific Reports 11 (1), 2591, 2021 | 12 | 2021 |
| Beneficial effects of mineralocorticoid receptor antagonism on myocardial fibrosis in an experimental model of the myxomatous degeneration of the mitral valve J Ibarrola, M Garaikoetxea, A Garcia-Peña, L Matilla, E Jover, B Bonnard, ... International Journal of Molecular Sciences 21 (15), 5372, 2020 | 12 | 2020 |
| Mineralocorticoid receptor antagonism prevents the synergistic effect of metabolic challenge and chronic kidney disease on renal fibrosis and inflammation in mice R Palacios-Ramirez, I Lima-Posada, B Bonnard, M Genty, ... Frontiers in Physiology 13, 859812, 2022 | 11 | 2022 |
| Endothelial sodium channel activation mediates DOCA-salt-induced endothelial cell and arterial stiffening L Zhang, Y Yang, AR Aroor, G Jia, Z Sun, A Parrish, G Litherland, ... Metabolism 130, 155165, 2022 | 9 | 2022 |
| Benefits of the non-steroidal mineralocorticoid receptor antagonist finerenone in metabolic syndrome-related heart failure with preserved ejection fraction I Lima-Posada, Y Stephan, M Soulié, R Palacios-Ramirez, B Bonnard, ... International Journal of Molecular Sciences 24 (3), 2536, 2023 | 4 | 2023 |
| Biglycan is a novel mineralocorticoid receptor target involved in aldosterone/salt-induced glomerular injury T Nakamura, B Bonnard, R Palacios-Ramirez, A Fernández-Celis, ... International Journal of Molecular Sciences 23 (12), 6680, 2022 | 3 | 2022 |
| NGAL is a novel target in hypertension by modulating the NCC-mediated renal NA balance B Bonnard, S El Moghrabi, K Ueda, L Lattenist, M Soulie, N López-Andrés, ... Hypertension 80 (9), 1860-1870, 2023 | 1 | 2023 |
| Spironolactone but not EPLERENONE exacerbates cisplatin nephrotoxicity GR Estrela, B Bonnard, J Barrera-Chimal, F Jaisser bioRxiv, 790998, 2019 | 1 | 2019 |
| Ngal Is A Novel Target In Hypertension By Modulating The Ncc-mediated Renal Na Balance F Jaisser, B Bonnard, T Shimosawa, C Xhaard, patrick rossignol Hypertension 80 (Suppl_1), A129-A129, 2023 | | 2023 |
| The Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction In Preclinical Non-diabetic Chronic Kidney Disease I Lima Posada, Y STEPHAN, M Soulié, R Palacios-Ramirez, B Bonnard, ... Hypertension 80 (Suppl_1), A080-A080, 2023 | | 2023 |
| PS-B09-6: BIGLYCAN, A NEWLY IDENTIFIED MEDIATOR OF MINERALOCORTICOID RECEPTOR ACTIVATION-INDUCED NEPHROPATHY T Nakamura, B Bonnard, RP Ramirez, AF Celis, F Jaisser, NL Andres Journal of Hypertension 41 (Suppl 1), e378, 2023 | | 2023 |
| The non-steroidal mineralocorticoid receptor antagonist finerenone improves left ventricular function in preclinical chronic kidney disease Y Stephan, I Lima-Posada, M Souille, B Bonnard, R Palacios, L Nicol, ... European Heart Journal 42 (Supplement_1), ehab724. 2933, 2021 | | 2021 |
| DOCA‐Salt‐Induced Endothelial Cell Stiffening Occurs Via mTORC2/SGK1 mediated Regulation of EnNaC L Zhang, Y Yang, A Annayya, G Jia, S Zhe, B Bonnard, F Jaisser, ... The FASEB Journal 35, 2021 | | 2021 |
